The company said it planned to seek Food and Drug Administration approval for the drug, orforglipron, before the end of the ...

Eli Lilly raised its full-year profit forecast on Thursday, betting on surging demand for its blockbuster weight-loss drug, ...

In the first Phase 3 trial of its once-daily oral GLP-1 pill in people with obesity, drugmaker Eli Lilly said Thursday that ...

Eli Lilly's pill, orforglipron, is one step closer to becoming the first new, needle-free alternative in the booming market ...

In eagerly awaited results from a new study, the pharmaceutical company Eli Lilly reports that a pill its scientists ...

Eli Lilly reported second quarter earnings Thursday, a day after competitor Novo Nordisk missed earnings estimates by Wall ...

Eli Lilly (LLY) stock plunges as Phase 3 trial data for the company's oral weight loss drug orforglipron overshadow better ...

Shares of Eli Lilly and Co. tumbled 12.8% in premarket trading Thursday, toward its biggest one-day selloff in 26 years, after the drug giant disclosed late-stage trial data for its oral weight-loss ...

Eli Lilly said on Thursday that its newer diabetes drug Mounjaro outperformed Trulicity, its previously top-selling ...

As other pharmas drop next-gen obesity assets, Eli Lilly’s experimental oral GLP-1 has prompted weight loss up to an average ...

Eli Lilly has hoped its candidate weight loss pill would safeguard its lead in the obesity market, but new results may prove ...